Crescita Therapeutics Inc. CTX.TO Stock
Crescita Therapeutics Inc. Price Chart
Crescita Therapeutics Inc. CTX.TO Financial and Trading Overview
Crescita Therapeutics Inc. stock price | 0.42 CAD |
Previous Close | 0.66 CAD |
Open | 0.66 CAD |
Bid | 0.65 CAD x 0 |
Ask | 0.66 CAD x 0 |
Day's Range | 0.66 - 0.66 CAD |
52 Week Range | 0.58 - 0.79 CAD |
Volume | 2.6K CAD |
Avg. Volume | 11.17K CAD |
Market Cap | 13.42M CAD |
Beta (5Y Monthly) | 1.913419 |
PE Ratio (TTM) | 13.200001 |
EPS (TTM) | -0.1 CAD |
Forward Dividend & Yield | N/A (N/A) |
Ex-Dividend Date | N/A |
1y Target Est | N/A |
CTX.TO Valuation Measures
Enterprise Value | 4.66M CAD |
Trailing P/E | 13.200001 |
Forward P/E | N/A |
PEG Ratio (5 yr expected) | N/A |
Price/Sales (ttm) | 0.579072 |
Price/Book (mrq) | 0.6439025 |
Enterprise Value/Revenue | 0.201 |
Enterprise Value/EBITDA | 2.644 |
Trading Information
Crescita Therapeutics Inc. Stock Price History
Beta (5Y Monthly) | 1.913419 |
52-Week Change | 8.19% |
S&P500 52-Week Change | 20.43% |
52 Week High | 0.79 CAD |
52 Week Low | 0.58 CAD |
50-Day Moving Average | 0.66 CAD |
200-Day Moving Average | 0.67 CAD |
CTX.TO Share Statistics
Avg. Volume (3 month) | 11.17K CAD |
Avg. Daily Volume (10-Days) | 5.11K CAD |
Shares Outstanding | 20.33M |
Float | 18.04M |
Short Ratio | 0.05 |
% Held by Insiders | 7.36% |
% Held by Institutions | 0% |
Shares Short | 503 |
Short % of Float | N/A |
Short % of Shares Outstanding | 0% |
Dividends & Splits
Trailing Annual Dividend Rate | 0 |
Trailing Annual Dividend Yield | 0% |
5 Year Average Dividend Yield | N/A |
Payout Ratio | 0 |
Last Split Factor |
Financial Highlights
Fiscal Year
Fiscal Year Ends | December 31, 2022 |
Most Recent Quarter (mrq) | March 31, 2023 |
Next Fiscal Year End | December 31, 2023 |
Profitability
Profit Margin | 4.58% |
Operating Margin (ttm) | 2.88% |
Gross Margin | 56.98% |
EBITDA Margin | 7.60% |
Management Effectiveness
Return on Assets (ttm) | 1.46% |
Return on Equity (ttm) | 5.20% |
Income Statement
Revenue (ttm) | 23.18M CAD |
Revenue Per Share (ttm) | 1.13 CAD |
Quarterly Revenue Growth (yoy) | -7.00000000000000089% |
Gross Profit (ttm) | 13.18M CAD |
EBITDA | 1.76M CAD |
Net Income Avi to Common (ttm) | 1.06M CAD |
Diluted EPS (ttm) | 0.05 |
Quarterly Earnings Growth (yoy) | N/A |
Balance Sheet
Total Cash (mrq) | 10.28M CAD |
Total Cash Per Share (mrq) | 0.51 CAD |
Total Debt (mrq) | 1.51M CAD |
Total Debt/Equity (mrq) | 7.26 CAD |
Current Ratio (mrq) | 3.543 |
Book Value Per Share (mrq) | 1.025 |
Cash Flow Statement
Operating Cash Flow (ttm) | 452K CAD |
Levered Free Cash Flow (ttm) | -295875 CAD |
Profile of Crescita Therapeutics Inc.
Country | Canada |
State | QC |
City | Laval |
Address | 2805 Place Louis-R Renaud |
ZIP | H7V 0A3 |
Phone | N/A |
Website | https://www.crescitatherapeutics.com |
Industry | Drug Manufacturers-Specialty & Generic |
Sector(s) | Healthcare |
Full Time Employees | N/A |
Crescita Therapeutics Inc., a dermatology company, provides non-prescription skincare products and prescription drug products in Canada, the United States, and internationally. The company operates through three segments: Commercial Skincare, Licensing and Royalties, and Manufacturing and Services. It owns proprietary platform technologies, including Multiplexed Molecular Penetration Enhancers (MMPE) and DuraPeel for the development of topicals containing cannabis and hemp. The company's prescription products include Pliaglis, a topical local anesthetic cream that provides dermal analgesia on intact skin prior to superficial dermatological procedures; CTX-101, a Phase III topical formulation utilizing a corticosteroid in combination with MMPE technology to treat plaque psoriasis; CTX-102, a Phase I topical formulation utilizing MMPE technology to treat an undisclosed dermatological skin condition; and dermatology products in pre-clinical formulation utilizing MMPE technology for prescription treatments of skin diseases. Its non-prescription portfolio offers dermocosmetic products, such as facial creams, cleansers, exfoliants, masks, serums, and suncare to treat mild acne, aging, dehydration, pigmentation, sensitivity, and rosacea under the Laboratoire Dr Renaud brand; and provides medical aesthetics under Pro-Derm and Alyria brands, for non-invasive and minimally invasive procedures or skincare treatments. In addition, it distributes NCTF Boost 135 HA, a skin revitalization solution; Obagi Medical products; and ART FILLER, hyaluronic acid-based dermal fillers. The company has a commercialization license agreement with Cantabria Labs Inc.; and a development and commercialization license agreement with Taro Pharmaceuticals Inc. Crescita Therapeutics Inc. was incorporated in 2016 and is headquartered in Laval, Canada.
Q&A For Crescita Therapeutics Inc. Stock
What is a current CTX.TO stock price?
Crescita Therapeutics Inc. CTX.TO stock price today per share is 0.42 CAD.
How to purchase Crescita Therapeutics Inc. stock?
You can buy CTX.TO shares on the Toronto exchange. Contact your financial advisor to select a broker.
What is the ticker symbol for Crescita Therapeutics Inc.?
The stock symbol or ticker of Crescita Therapeutics Inc. is CTX.TO.
Which industry does the Crescita Therapeutics Inc. company belong to?
The Crescita Therapeutics Inc. industry is Drug Manufacturers-Specialty & Generic.
How many shares does Crescita Therapeutics Inc. have in circulation?
The max supply of Crescita Therapeutics Inc. shares is 19.54M.
What is Crescita Therapeutics Inc. Price to Earnings Ratio (PE Ratio)?
Crescita Therapeutics Inc. PE Ratio is now.
What was Crescita Therapeutics Inc. earnings per share over the trailing 12 months (TTM)?
Crescita Therapeutics Inc. EPS is -0.1 CAD over the trailing 12 months.
Which sector does the Crescita Therapeutics Inc. company belong to?
The Crescita Therapeutics Inc. sector is Healthcare.